Interesting comment in the latest edition of Bioshares in response to the 206% increase in share price over the Dec quarter:
This was driven by the expectation of a deal being signed with a commercial partner for the company's wound healing compound VitroGro. However the start of UK trial involving 40 patients appears to have been pushed back due to bad weather.
Add to My Watchlist
What is My Watchlist?